FDA Panel Will Have To Resolve Bleeding Risk With Merck’s Vorapaxar
This article was originally published in The Pink Sheet Daily
Executive Summary
Novel antiplatelet product has suffered from excess bleeding rates in clinical trials and is searching for an appropriate patient population, after initial hopes of being a blockbuster.